Biomunex Pharmaceuticals Overview
- Founded
-
2014
- Status
-
Private
- Employees
-
8
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$3.48M
- Investors
-
5
Biomunex Pharmaceuticals General Information
Description
Developer of immunotherapies designed to deliver therapeutics in the area of immuno-oncology. The company's immunotherapies offer to develop drug candidates with high anti-tumor potential, superior manufacturability, and optimal drug-like properties, enabling biotechnology companies to format antibodies from any pair of monospecific monoclonal antibodies as building blocks in a timely and cost-effective manner.
Contact Information
Website
www.biomunex.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 14 avenue d'Eylau
- 75116 Paris
- France
Biomunex Pharmaceuticals Timeline
Biomunex Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Grant | 03-Nov-2021 | $3.48M | 00.000 | Completed | Generating Revenue | |
| 5. Later Stage VC (Series A) | 16-Feb-2021 | 00.000 | 00.000 | 000.00 | Completed | Generating Revenue |
| 4. Seed Round | Completed | Startup | ||||
| 3. Accelerator/Incubator | Completed | Startup | ||||
| 2. Grant | 01-Jan-2016 | Completed | Startup | |||
| 1. Grant | 01-Jan-2014 | Completed | Startup |
Biomunex Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | 000,000 | 00.000000 | 000.0 | 000.0 | 00 | 000.0 | 00.00 |
Biomunex Pharmaceuticals Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of immunotherapies designed to deliver therapeutics in the area of immuno-oncology. The company's immunotherap
Drug Discovery
Paris, France
8
As of 2022
00.000
0000000000
00.000
00 000
derit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupida
0000000000000
Durham, NC
000
As of 0000
00000
000000 - 000
00000
000 00
it amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna ali
0000 000000000
Barcelona, Spain
00
As of 0000
0000
00000000000
0000
Add Comparison
Biomunex Pharmaceuticals Competitors (8)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| G1 Therapeutics | Formerly VC-backed | Durham, NC | 000 | 00000 | 000000 - 000 | 00000 |
| 000 000000000000 | Venture Capital-Backed | Barcelona, Spain | 00 | 0000 | 00000000000 | 0000 |
| 00000000 | Venture Capital-Backed | Boston, MA | 00 | 0000 | 00000000000 | 0000 |
| 0000000 000000 | Venture Capital-Backed | Barcelona, Spain | 00 | 0000 | 000000000000 | 0000 |
| 0000000-00000 0000 | Corporation | New York, NY | 00000 | 00000 | 000000000 | 00000 |
Biomunex Pharmaceuticals Patents
Biomunex Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3565847-A1 | A polypeptide linker for preparing multispecific antibodies | Pending | 09-Jan-2017 | 0000000000 | |
| CA-3052084-A1 | A polypeptide linker for preparing multispecific antibodies | Pending | 09-Jan-2017 | 0000000000 | |
| JP-2020503873-A | Polypeptide linkers for preparing multispecific antibodies | Pending | 09-Jan-2017 | 0000000000 | 00 |
| AU-2018206229-A1 | A polypeptide linker for preparing multispecific antibodies | Pending | 09-Jan-2017 | 0000000000 | |
| US-20190330377-A1 | A polypeptide linker for preparing multispecific antibodies | Pending | 09-Jan-2017 | C07K16/468 |
Biomunex Pharmaceuticals Executive Team (6)
Biomunex Pharmaceuticals Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alain Dublin | Self | Board Member | 000 0000 |
| C. Grace Yeh | Onward Therapeutics | Board Member | 000 0000 |
| Dragan Grabulovski Ph.D | Self | Board Observer | 000 0000 |
| Eugene Zhukovsky Ph.D | Biomunex Pharmaceuticals | Chief Technology Officer & Board Member | 000 0000 |
| Jordi Esclusa | Self | Board Member | 000 0000 |
Biomunex Pharmaceuticals Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Biomunex Pharmaceuticals Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| French Government | Government | Minority | 000 0000 | 000000 0 | |
| Onward Therapeutics | Corporation | Minority | 000 0000 | 000000 0 | |
| L'Agence Nationale de la Recherche | Government | 000 0000 | 000000 0 | ||
| Bpifrance | Sovereign Wealth Fund | 000 0000 | 000000 0 | ||
| Agoranov | Accelerator/Incubator | Minority | 000 0000 | 000000 0 |